# Package 'DelayedEffect.Design'

October 16, 2017

APPLE+ and SEPPLE+ Methods	
Version 1.0.0	
<b>Date</b> 2017-10-16	
Author  Zhenzhen Xu <zhenzhen. xu@fda.hhs.gov="">, Boguang Zhen<boguang.zhen@fda.hhs.gov>, Y soek Park <yongpark@pitt.edu> and Bin Zhu <bin.zhu@nih.gov></bin.zhu@nih.gov></yongpark@pitt.edu></boguang.zhen@fda.hhs.gov></zhenzhen.>	ong-
<b>Description</b> Provides sample size and power calculations when the treatment time-lag effect is present and the lag duration is either homogeneous across the individual subject, or varies heterogeneously from individual to individual within a certain domain and following a specific pattern. The methods used are described in Xu, Z., Zhen, B., Park, Y., & Zhu, B. (2017) <doi:10.1002 sim.7157="">.</doi:10.1002>	
Maintainer Bill Wheeler < wheeler b@imsweb.com>	
License GPL-2	
NeedsCompilation yes	
R topics documented:	
DelayedEffect.Design	2
HR.APPLE	3
HR.APPLE.plus	1
N.APPLE	5
N.APPLE.plus	
pow.APPLE	
pow.APPLE.plus	
pow.SEPPLE	
pow.SEPPLE.plus	
pow.SEPPLE.random.DE	
pow.sim.logrk	•
Index 18	3

DelayedEffect.Design Sample size and power calculations using the APPLE, SEPPLE, AP-PLE+ and SEPPLE+ methods

### **Description**

2

An R package for sample size and power calculation when the treatment time-lag effect is present. The package incorporates two specific lag assumptions:

- 1. the lag duration is homogeneous across the individual subject;
- 2. the lag duration varies heterogeneously from individual to individual within a certain domain and following a specific pattern.

#### **Details**

The four new methods in this package for performing the sample size and power calculations are:

- 1. Analytic Power calculation method based on Piecewise weighted Log-rank tEst (APPLE),
- 2. Simulation-based Empirical Power calculation method based on Piecewise weighted Log-rank tEst (SEPPLE),
- 3. Analytic Power calculation method based on generalized Piecewise weighted Log-rank tEst with random treatment time-lag effect (APPLE+),
- 4. Simulation-based Empirical Power calculation method based on generalized Piecewise weighted Log-rank tEst with random treatment time-lag effect (SEPPLE+).

See the reference for details of these methods. Specifically, APPLE and SEPPLE assume that the lag duration is homogeneous across the individual subject, whereas APPLE and SEPPLE assume that the lag duration varies heterogeneously from individual to individual or from study to study within a certain domain and following a specific pattern. The functions for computing power corresponding to the above methods are pow.APPLE, pow.SEPPLE, pow.APPLE.plus, pow.SEPPLE.plus and pow.SEPPLE.random.DE. These can be compared to pow.sim.logrk and pow.sim.logrk.rankdom.DE which compute the power from a simulation-based algorithm using the regular log-rank test which ignores the existence of lag effects. The package also includes the function N.APPLE, N.APPLE.plus to back calculate the sample size given the power and hazard ratio, and the functions HR.APPLE and HR.APPLE.plus to back calculate the hazard ratio given the power and sample size, respectively, using the close-from APPLE and APPLE+ methods.

#### Author(s)

Zhenzhen Xu <Zhenzhen.Xu@fda.hhs.gov>, Boguang Zhen<Boguang.Zhen@fda.hhs.gov>, Yongsoek Park <yongpark@pitt.edu> and Bin Zhu <br/>bin.zhu@nih.gov>

## References

Xu, Z., Park, Y., Zhen, B. & Zhu, B. (2017). Achieving optimal power of logrank test with random treatment time-lag effect. Biometrika. Under review.

Xu, Z., Zhen, B., Park, Y., & Zhu, B. (2017). Designing therapeutic cancer vaccine trials with delayed treatment effect. Statistics in medicine, 36(4), 592-605.

HR.APPLE 3

HR.APPLE	APPLE hazard ratio computation	

# **Description**

Perform the post-delay hazard ratio calculation given power and sample size using the close-form APPLE method based on the piecewise weighted log-rank test when the treatment time-lag effect is present and the lag duration is homogeneous across the individual subject

# Usage

```
HR.APPLE(lambda1, t1, p, N, tao, A, beta, ap=0.5, alpha=0.05)
```

# **Arguments**

lambda1	Baseline hazard or NULL (see details)
t1	Delayed duration or NULL (see details)
p	Proportion of subjects who survive beyond the delayed period or NULL (see details)
N	Sample size
tao	Total study duration
Α	Total enrollment duration
beta	Type II error rate; Power=1-beta
ар	Experimental-control allocation ratio. The default is 0.5.
alpha	Type I error rate (two-sided). The default is 0.05.

### **Details**

APPLE is an acronym for:

Analytic Power calculation method based on Piecewise weighted Log-rank tEst. See the reference for details of this method.

Out of the three input parameters lambda1, t1 and p, only two need to be specified, the remaining one will be computed internally from the formula lambda1 =  $-\log(p)/t1$ . If all three are not NULL, then lambda1 will be set to  $-\log(p)/t1$  regardless of the user input value.

# Value

The hazard ratio

# Author(s)

Zhenzhen Xu <Zhenzhen.Xu@fda.hhs.gov>, Boguang Zhen<Boguang.Zhen@fda.hhs.gov>, Yongsoek Park <yongpark@pitt.edu> and Bin Zhu <br/>bin.zhu@nih.gov>

# References

Xu, Z., Zhen, B., Park, Y., & Zhu, B. (2017). Designing therapeutic cancer vaccine trials with delayed treatment effect. Statistics in medicine, 36(4), 592-605.

4 HR.APPLE.plus

### See Also

```
pow.APPLE, N.APPLE
```

# **Examples**

```
lambda1 <- NULL

t1 <- 183

p <- 0.7

N <- 200

tao <- 365*3

A <- 365

beta <- 0.2

HR.APPLE(lambda1, t1, p, N, tao, A, beta)
```

HR.APPLE.plus

APPLE+ hazard ratio computation

# **Description**

Perform the post-delay hazard ratio calculation given power and sample size using the close-form APPLE+ method based on the generalized piecewise weighted log-rank test when the treatment time-lag effect is present and the lag duration varies heterogeneously from individual to individual or from study to study, within a certain domain and following a specific pattern.

### Usage

```
HR.APPLE.plus(lambda1, tl, tu, N, tao, A, beta, ap=0.5, alpha=0.05)
```

# **Arguments**

lambda1	Baseline hazard
tl	Lower bound of delayed duration domain
tu	Upper bound of delayed duration domain
N	Sample size
tao	Total study duration
A	Total enrollment duration
beta	Type II error rate; Power=1-beta
ар	Experimental-control allocation ratio. The default is 0.5.
alpha	Type I error rate (two-sided). The default is 0.05.

# **Details**

APPLE+ is an acronym for:

Analytic Power calculation method based on generalized Piecewise weighted Log-rank tEst with random treatment time-lag effect. See the reference for details of this method.

# Value

The hazard ratio

N.APPLE 5

#### Author(s)

Zhenzhen Xu <Zhenzhen.Xu@fda.hhs.gov>, Boguang Zhen<Boguang.Zhen@fda.hhs.gov>, Yongsoek Park <yongpark@pitt.edu> and Bin Zhu <br/>bin.zhu@nih.gov>

### References

Xu, Z., Park, Y., Zhen, B. & Zhu, B. (2017). Achieving optimal power of logrank test with random treatment time-lag effect. Biometrika. Under review.

Xu, Z., Zhen, B., Park, Y., & Zhu, B. (2017). Designing therapeutic cancer vaccine trials with delayed treatment effect. Statistics in medicine, 36(4), 592-605.

# See Also

```
pow.APPLE.plus, N.APPLE.plus
```

# **Examples**

```
lambda1 <- 0.001982

tl <- 30

tu <- 30*11

N <- 200

tao <- 365*3

A <- 365

beta <- 0.2

HR.APPLE.plus(lambda1, tl, tu, N, tao, A, beta)
```

N.APPLE

APPLE sample size computation

# Description

Perform the sample size calculation given the power and post-delay hazard ratio using the closeform APPLE method based on the piecewise weighted log-rank test when the treatment time-lag effect is present and the lag duration is homogeneous across the individual subject

# Usage

```
N.APPLE(lambda1, t1, p, HR, tao, A, beta, ap=0.5, alpha=0.05)
```

### **Arguments**

lambda1	Baseline hazard or NULL (see details)
t1	Delayed duration or NULL (see details)
p	Proportion of subjects who survive beyond the delayed period or NULL (see details)
HR	Post-delay hazard ratio, defined as the post-delay hazard rate of the treatment group compared to that of the control group
tao	Total study duration
A	Total enrollment duration
beta	Type II error rate; Power=1-beta
ар	Experimental-control allocation ratio. The default is 0.5.
alpha	Type I error rate (two-sided). The default is 0.05.

6 N.APPLE.plus

#### **Details**

APPLE is an acronym for:

Analytic Power calculation method based on Piecewise weighted Log-rank tEst. See the reference for details of this method.

Out of the three input parameters lambda1, t1 and p, only two need to be specified, the remaining one will be computed internally from the formula lambda1 = -log(p)/t1. If all three are not NULL, then lambda1 will be set to -log(p)/t1 regardless of the user input value.

#### Value

The sample size

### Author(s)

Zhenzhen Xu <Zhenzhen.Xu@fda.hhs.gov>, Boguang Zhen<Boguang.Zhen@fda.hhs.gov>, Yongsoek Park <yongpark@pitt.edu> and Bin Zhu <br/>bin.zhu@nih.gov>

### References

Xu, Z., Zhen, B., Park, Y., & Zhu, B. (2017). Designing therapeutic cancer vaccine trials with delayed treatment effect. Statistics in medicine, 36(4), 592-605.

### See Also

```
pow.APPLE, HR.APPLE
```

# **Examples**

```
lambda1 <- NULL

t1 <- 183

p <- 0.7

HR <- 0.55

tao <- 365*3

A <- 365

beta <- 0.2

N.APPLE(lambda1, t1, p, HR, tao, A, beta)
```

N.APPLE.plus

APPLE+ sample size computation

### **Description**

Perform the sample size calculation given the power and post-delay hazard ratio using the close-form APPLE+ method based on the generalized piecewise weighted log-rank test when the treatment time-lag effect is present and the lag duration varies heterogeneously from individual to individual or from study to study, within a certain domain and following a specific pattern.

# Usage

```
N.APPLE.plus(lambda1, tl, tu, HR, tao, A, beta, ap=0.5, alpha=0.05)
```

N.APPLE.plus 7

# **Arguments**

lambda1	Baseline hazard
tl	Lower bound of delayed duration domain
tu	Upper bound of delayed duration domain
HR	Post-delay hazard ratio after tu, defined as the post-delay hazard rate of the treatment group compared to that of the control group
tao	Total study duration
A	Total enrollment duration
beta	Type II error rate; Power=1-beta
ар	Experimental-control allocation ratio. The default is 0.5.
alpha	Type I error rate (two-sided). The default is 0.05.

#### **Details**

APPLE+ is an acronym for:

Analytic Power calculation method based on generalized Piecewise weighted Log-rank tEst with random treatment time-lag effect. See the reference for details of this method.

### Value

The sample size

# Author(s)

Zhenzhen Xu <Zhenzhen.Xu@fda.hhs.gov>, Boguang Zhen<Boguang.Zhen@fda.hhs.gov>, Yongsoek Park <yongpark@pitt.edu> and Bin Zhu <br/>bin.zhu@nih.gov>

# References

Xu, Z., Park, Y., Zhen, B. & Zhu, B. (2017). Achieving optimal power of logrank test with random treatment time-lag effect. Biometrika. Under review.

Xu, Z., Zhen, B., Park, Y., & Zhu, B. (2017). Designing therapeutic cancer vaccine trials with delayed treatment effect. Statistics in medicine, 36(4), 592-605.

# See Also

```
pow.APPLE.plus, HR.APPLE.plus
```

# **Examples**

```
lambda1 <- 0.001982

tl <- 30

tu <- 30*11

HR <- 1.3

tao <- 365*3

A <- 365

beta <- 0.2

N.APPLE.plus(lambda1, tl, tu, HR, tao, A, beta)
```

pow.APPLE

# **Description**

Perform the power calculation using the close-form APPLE method based on the piecewise weighted log-rank test when the treatment time-lag effect is present and the lag duration is homogeneous across the individual subject

# Usage

```
pow.APPLE(lambda1, t1, p, N, HR, tao, A, ap=0.5, alpha=0.05)
```

# Arguments

lambda1	Baseline hazard or NULL (see details)
t1	Delayed duration or NULL (see details)
p	Proportion of subjects who survive beyond the delayed period or NULL (see details)
N	Sample size
HR	Post-delay hazard ratio, defined as the post-delay hazard rate of the treatment group compared to that of the control group
tao	Total study duration
Α	Total enrollment duration
ар	Experimental-control allocation ratio. The default is 0.5.
alpha	Type I error rate (two-sided). The default is 0.05.

# **Details**

APPLE is an acronym for:

Analytic Power calculation method based on Piecewise weighted Log-rank tEst. See the reference for details of this method.

Out of the three input parameters lambda1, t1 and p, only two need to be specified, the remaining one will be computed internally from the formula lambda1 =  $-\log(p)/t1$ . If all three are not NULL, then lambda1 will be set to  $-\log(p)/t1$  regardless of the user input value.

# Value

The power

# Author(s)

Zhenzhen Xu <Zhenzhen.Xu@fda.hhs.gov>, Boguang Zhen<Boguang.Zhen@fda.hhs.gov>, Yongsoek Park <yongpark@pitt.edu> and Bin Zhu <br/>bin.zhu@nih.gov>

# References

Xu, Z., Zhen, B., Park, Y., & Zhu, B. (2017). Designing therapeutic cancer vaccine trials with delayed treatment effect. Statistics in medicine, 36(4), 592-605.

pow.APPLE.plus 9

#### See Also

```
N. APPLE, HR. APPLE, pow. SEPPLE, pow. sim. logrk
```

### **Examples**

```
lambda1 <- NULL

t1 <- 183

p <- 0.7

N <- 200

HR <- 0.55

tao <- 365*3

A <- 365

pow.APPLE(lambda1, t1, p, N, HR, tao, A)
```

pow.APPLE.plus

APPLE+ power computation

# **Description**

Perform the power calculation using the close-form APPLE+ method based on the generalized piecewise weighted log-rank test when the treatment time-lag effect is present and the lag duration varies heterogeneously from individual to individual or from study to study, within a certain domain and following a specific pattern.

# Usage

```
pow.APPLE.plus(lambda1, tl, tu, N, HR, tao, A, ap=0.5, alpha=0.05)
```

# **Arguments**

lambda1	Baseline hazard
tl	Lower bound of delayed duration domain
tu	Upper bound of delayed duration domain
N	Sample size
HR	Post-delay hazard ratio after tu, defined as the post-delay hazard rate of the treatment group compared to that of the control group
tao	Total study duration
Α	Total enrollment duration
ар	Experimental-control allocation ratio. The default is 0.5.
alpha	Type I error rate (two-sided). The default is 0.05.

# **Details**

APPLE+ is an acronym for:

Analytic Power calculation method based on generalized Piecewise weighted Log-rank tEst with random treatment time-lag effect. See the reference for details of this method.

# Value

The power

10 pow.SEPPLE

#### Author(s)

Zhenzhen Xu <Zhenzhen.Xu@fda.hhs.gov>, Boguang Zhen<Boguang.Zhen@fda.hhs.gov>, Yongsoek Park <yongpark@pitt.edu> and Bin Zhu <br/>bin.zhu@nih.gov>

#### References

Xu, Z., Park, Y., Zhen, B. & Zhu, B. (2017). Achieving optimal power of logrank test with random treatment time-lag effect. Biometrika. Under review.

Xu, Z., Zhen, B., Park, Y., & Zhu, B. (2017). Designing therapeutic cancer vaccine trials with delayed treatment effect. Statistics in medicine, 36(4), 592-605.

#### See Also

```
N.APPLE.plus, HR.APPLE.plus
```

# **Examples**

pow.SEPPLE

SEPPLE power computation

# **Description**

Perform the power calculation using the numeric SEPPLE method based on the piecewise weighted log-rank test when the treatment time-lag effect is present and the lag duration is homogeneous across the individual subject

# Usage

```
pow.SEPPLE(lambda1, t1, p, N, HR, tao, A, ap=0.5, alpha=0.05, nsim=10000)
```

### **Arguments**

lambda1	Baseline hazard or NULL (see details)
t1	Delayed duration or NULL (see details)
p	Proportion of subjects who survive beyond the delayed period or NULL (see details)
N	Sample size
HR	Post-delay hazard ratio, defined as the post-delay hazard rate of the treatment group compared to that of the control group
tao	Total study duration
Α	Total enrollment duration

pow.SEPPLE.plus 11

ар	Experimental-control allocation ratio. The default is 0.5.
----	--

alpha Type I error rate (two-sided). The default is 0.05.

Number of simulations. The default is 10000.

#### **Details**

SEPPLE is an acronym for:

Simulation-based Empirical Power calculation method based on Piecewise weighted Log-rank tEst. See the reference for details of this method.

Out of the three input parameters lambda1, t1 and p, only two need to be specified, the remaining one will be computed internally from the formula lambda1 =  $-\log(p)/t1$ . If all three are not NULL, then lambda1 will be set to  $-\log(p)/t1$  regardless of the user input value.

#### Value

The power

# Author(s)

Zhenzhen Xu <Zhenzhen.Xu@fda.hhs.gov>, Boguang Zhen<Boguang.Zhen@fda.hhs.gov>, Yongsoek Park <yongpark@pitt.edu> and Bin Zhu <bir>bin.zhu@nih.gov>

#### References

Xu, Z., Zhen, B., Park, Y., & Zhu, B. (2017). Designing therapeutic cancer vaccine trials with delayed treatment effect. Statistics in medicine, 36(4), 592-605.

#### See Also

```
pow.APPLE, pow.sim.logrk
```

# **Examples**

```
lambda1 <- NULL

t1 <- 183

p <- 0.7

N <- 200

HR <- 0.55

tao <- 365*3

A <- 365

pow.SEPPLE(lambda1, t1, p, N, HR, tao, A, nsim=1000)
```

```
pow.SEPPLE.plus
```

SEPPLE+ power computation

# Description

Perform the power calculation using the numeric SEPPLE+ method based on the generalized piecewise weighted log-rank test when the treatment time-lag effect is present and the lag duration varies heterogeneously from individual to individual or from study to study, within a certain domain and following a specific pattern.

12 pow.SEPPLE.plus

#### Usage

# **Arguments**

lambda1	Baseline hazard
tl	Lower bound of delayed duration domain
tu	Upper bound of delayed duration domain
N	Sample size
HR	Post-delay hazard ratio after tu, defined as the post-delay hazard rate of the treatment group compared to that of the control group
tao	Total study duration
A	Total enrollment duration
dist	One of "uniform", "beta" or "gamma", for the lag distribution
shape1	NULL or a positive parameter value for the beta or gamma distribution.
shape2	NULL or a positive parameter value for the beta or gamma distribution.
ар	Experimental-control allocation ratio. The default is 0.5.
alpha	Type I error rate (two-sided). The default is 0.05.
nsim	Number of simulations. The default is 10000.

### **Details**

SEPPLE+ is an acronym for:

Simulation-based Empirical Power calculation method based on generalized Piecewise weighted Log-rank tEst with random treatment time-lag effect. See the reference for details of this method.

# Value

The power

### Author(s)

Zhenzhen Xu <Zhenzhen.Xu@fda.hhs.gov>, Boguang Zhen<Boguang.Zhen@fda.hhs.gov>, Yongsoek Park <yongpark@pitt.edu> and Bin Zhu <bir>bin.zhu@nih.gov>

# References

Xu, Z., Park, Y., Zhen, B. & Zhu, B. (2017). Achieving optimal power of logrank test with random treatment time-lag effect. Biometrika. Under review.

Xu, Z., Zhen, B., Park, Y., & Zhu, B. (2017). Designing therapeutic cancer vaccine trials with delayed treatment effect. Statistics in medicine, 36(4), 592-605.

### See Also

```
\verb"pow.SEPPLE.random.DE", \verb"pow.sim.log" rk.random.DE"
```

### **Examples**

pow.SEPPLE.random.DE SEPPLE+ power computation

# Description

Perform the power calculation using the numeric SEPPLE method based on the piecewise weighted log-rank test when the treatment time-lag effect is present and the lag duration varies heterogeneously from individual to individual or from study to study, within a certain domain and following a specific pattern. The purpose of this function is to evaluate the property of SEPPLE which assumes the lag duration is homogeneous across the individual subject, when applied under the random scenario where the lag duration, in fact, varies heterogeneously.

# Usage

# **Arguments**

lambda1	Baseline hazard
tl	Lower bound of delayed duration domain
tu	Upper bound of delayed duration domain
N	Sample size
HR	Post-delay hazard ratio after tu, defined as the post-delay hazard rate of the treatment group compared to that of the control group
tao	Total study duration
A	Total enrollment duration
t.fixed	Fixed duration in SEPPLE
dist	One of "uniform", "beta" or "gamma", for the lag distribution
shape1	NULL or a positive parameter value for the beta or gamma distribution.
shape2	NULL or a positive parameter value for the beta or gamma distribution.
ар	Experimental-control allocation ratio. The default is 0.5.
alpha	Type I error rate (two-sided). The default is 0.05.
nsim	Number of simulations. The default is 10000.

14 pow.sim.logrk

#### **Details**

SEPPLE+ is an acronym for:

Simulation-based Empirical Power calculation method based on generalized Piecewise weighted Log-rank tEst with random treatment time-lag effect. See the reference for details of this method.

### Value

The power

### Author(s)

Zhenzhen Xu <Zhenzhen.Xu@fda.hhs.gov>, Boguang Zhen<Boguang.Zhen@fda.hhs.gov>, Yongsoek Park <yongpark@pitt.edu> and Bin Zhu <bir>bin.zhu@nih.gov>

### References

Xu, Z., Park, Y., Zhen, B. & Zhu, B. (2017). Achieving optimal power of logrank test with random treatment time-lag effect. Biometrika. Under review.

Xu, Z., Zhen, B., Park, Y., & Zhu, B. (2017). Designing therapeutic cancer vaccine trials with delayed treatment effect. Statistics in medicine, 36(4), 592-605.

#### See Also

```
pow.SEPPLE.plus, pow.sim.logrk.random.DE
```

# **Examples**

```
lambda1 <- 0.001982
tl
       <- 30
tu
       <- 30*11
N
        <- 200
HR
       <- 0.55
       <- 365*3
tao
        <- 365
t.fixed <- (tl+tu)/2
shape1 <- 5
shape2 <- 5
pow.SEPPLE.random.DE(lambda1, tl, tu, N, HR, tao, A, t.fixed, dist="beta",
                     shape1=shape1, shape2=shape2, nsim=1000)
```

pow.sim.logrk

Simulated log-rank power computation

# Description

Perform the power calculation using a simulation-based method based on the regular log-rank test when the treatment time-lag effect is present and the lag duration is homogeneous across the individual subject

# Usage

```
pow.sim.logrk(lambda1, t1, p, N, HR, tao, A, ap=0.5, alpha=0.05, nsim=10000)
```

pow.sim.logrk 15

#### **Arguments**

lambda1	Baseline hazard or NULL (see details)
t1	Delayed duration or NULL (see details)
p	Proportion of subjects who survive beyond the delayed period or NULL (see details)
N	Sample size
HR	Post-delay hazard ratio, defined as the post-delay hazard rate of the treatment group compared to that of the control group
tao	Total study duration
A	Total enrollment duration
ар	Experimental-control allocation ratio. The default is 0.5.
alpha	Type I error rate (two-sided). The default is 0.05.
nsim	Number of simulations. The default is 10000.

### **Details**

Out of the three input parameters lambda1, t1 and p, only two need to be specified, the remaining one will be computed internally from the formula lambda1 =  $-\log(p)/t1$ . If all three are not NULL, then lambda1 will be set to  $-\log(p)/t1$  regardless of the user input value.

### Value

The power

### Author(s)

Zhenzhen Xu <Zhenzhen.Xu@fda.hhs.gov>, Boguang Zhen<Boguang.Zhen@fda.hhs.gov>, Yongsoek Park <yongpark@pitt.edu> and Bin Zhu <br/>bin.zhu@nih.gov>

### References

Xu, Z., Zhen, B., Park, Y., & Zhu, B. (2017). Designing therapeutic cancer vaccine trials with delayed treatment effect. Statistics in medicine, 36(4), 592-605.

# See Also

```
pow. APPLE, pow. SEPPLE
```

# **Examples**

```
pow.sim.logrk.random.DE
```

Simulated log-rank power computation

# Description

Perform the power calculation using a simulation-based method based on the regular log-rank test when the treatment time-lag effect is present and the lag duration varies heterogeneously from individual to individual or from study to study, within a certain domain and following a specific pattern.

# Usage

# **Arguments**

lambda1	Baseline hazard
tl	Lower bound of delayed duration domain
tu	Upper bound of delayed duration domain
N	Sample size
HR	Post-delay hazard ratio after tu, defined as the post-delay hazard rate of the treatment group compared to that of the control group
tao	Total study duration
Α	Total enrollment duration
dist	One of "uniform", "beta" or "gamma", for the lag distribution
shape1	NULL or a positive parameter value for the beta or gamma distribution.
shape2	NULL or a positive parameter value for the beta or gamma distribution.
ар	Experimental-control allocation ratio. The default is 0.5.
alpha	Type I error rate (two-sided). The default is 0.05.
nsim	Number of simulations. The default is 10000.

# **Details**

The regular log-rank test is used here

# Value

The power

# Author(s)

### References

Xu, Z., Park, Y., Zhen, B. & Zhu, B. (2017). Achieving optimal power of logrank test with random treatment time-lag effect. Biometrika. Under review.

Xu, Z., Zhen, B., Park, Y., & Zhu, B. (2017). Designing therapeutic cancer vaccine trials with delayed treatment effect. Statistics in medicine, 36(4), 592-605.

# See Also

```
pow.SEPPLE.plus, pow.SEPPLE.random.DE
```

# **Examples**

```
lambda1 <- 0.001982
tl
       <- 30
        <- 30*11
tu
Ν
        <- 200
HR
        <- 0.55
       <- 365*3
tao
        <- 365
Α
shape1 <- 5
shape2 <- 5
pow.sim.logrk.random.DE(lambda1, tl, tu, N, HR, tao, A, dist="beta",
                        shape1=shape1, shape2=shape2, nsim=1000)
```

# **Index**

```
*Topic package
    DelayedEffect.Design, 2
*Topic power
    HR. APPLE, 3
    HR.APPLE.plus, 4
    N.APPLE, 5
    N.APPLE.plus, 6
    pow.APPLE, 8
    pow.APPLE.plus, 9
    pow. SEPPLE, 10
    {\tt pow.SEPPLE.plus}, {\tt 11}
    pow.SEPPLE.random.DE, 13
    pow.sim.logrk, 14
    pow.sim.logrk.random.DE, 16
DelayedEffect.Design, 2
HR. APPLE, 3, 6, 9
HR.APPLE.plus, 4, 7, 10
N. APPLE, 4, 5, 9
N.APPLE.plus, 5, 6, 10
pow.APPLE, 4, 6, 8, 11, 15
pow.APPLE.plus, 5, 7, 9
pow. SEPPLE, 9, 10, 15
pow. SEPPLE.plus, 11, 14, 17
pow.SEPPLE.random.DE, 12, 13, 17
pow.sim.logrk, 9, 11, 14
pow.sim.logrk.random.DE, 12, 14, 16
```